Method of treating cancer with ferric iron chelator and differentiation-inducing agent

A combination of ferric iron chelators and differentiation-inducing agents addresses the limitations of current cancer treatments by inducing terminal differentiation in cancer cells, achieving effective remission with reduced toxicity across various cancer types.

WO2026241209A1PCT designated stage Publication Date: 2026-11-19ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027708
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current cancer treatments, such as polychemotherapy and allogeneic bone marrow transplantation, cause significant damage to healthy tissues and lack applicability across various cancers, especially for non-APL AML, and non-cytotoxic differentiation therapies are inadequate.

Method used

A combination therapy using ferric iron chelators and differentiation-inducing agents, such as all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), is administered to restore terminal differentiation in cancer cells, including AML and solid tumors, without cytotoxicity.

Benefits of technology

The combination therapy effectively induces terminal differentiation in cancer cells, leading to remission and reduced risk of secondary malignancies, suitable for a wide range of cancers, including TP53 deficient cases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027708_19112026_PF_FP_ABST
    Figure US2026027708_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are compositions comprising at least one iron chelator, such as deferoxamine, deferasirox and deferiprone, and at least one differentiation-inducing agent, such as all-trans retinoic acid, arsenic trioxide and a menin inhibitor, for restoring terminal differentiation in cancer cells. In particular, provided are methods utilizing such compositions for treating cancers, such as acute myeloid leukemia and myelodysplastic syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Docket No. 182219.00305

[0002] METHOD OF TREATING CANCER WITH FERRIC IRON CHELATOR AND DIFFERENTIATION-INDUCING AGENT

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application is entitled to priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Application No. 63 / 804,042, filed on May 12, 2025. The content of the application is incorporated herein by reference in its entirety.

[0004] REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0005] The contents of the electronic sequence listing (182219.00305SeqList.xml; Size: 2,030 bytes; and Date of Creation: May 7, 2026) are herein incorporated by reference in their entirety.

[0006] FIELD OF THE INVENTION

[0007] This disclosure relates generally to methods and compositions for restoring terminal differentiation in cancer cells.

[0008] BACKGROUND OF THE INVENTION

[0009] All cancers share two fundamental features: they lose their ability to terminally differentiate and / or establish mature cell function, as well as they gain aberrant self-renewal. Many cancers, including adult tissue-specific stem cell-originating myeloid malignancies -acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), lack curative treatment options due to the persistence of therapy-refractory cells. Even for cancers that can be treated and potentially cured, currently employed regimens, such as polychemotherapy and allogeneic bone marrow transplantation, come at the cost of massive damage to healthy tissues and stem cells and life-long immune-suppression; imposing a considerable risk of treatment-associated secondary malignancies.

[0010] Moreover, highly cytotoxic therapies are often not suitable for a substantial number of patients with cancer due to co-morbidities, advanced age, or the presence of TP53 mutations in malignant cells. Molecularly-targeted differentiation therapies have been successfully developed for small subsets of cancers. A prime example is a combination of ATRA / ATO which has been shown to drive degradation of the differentiation-blocking oncogenic fusion protein PML-RARA in patients with acute promyelocytic leukemia (APL). APL has remained the only cancer curable by a non-cytotoxic differentiation therapy. Unfortunately, other non-cytotoxic differentiation restoring therapies currently fall short of eliciting cures as well as they

[0011] 1

[0012] 185360739.1Docket No. 182219.00305

[0013] lack general applicability within AML, let alone across cancers. Thus, there remains a need to develop non-cytotoxic differentiation therapies to treat cancer such as non-APL AML.

[0014] SUMMARY OF THE INVENTION

[0015] In one aspect, provided is a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one iron chelator in combination with at least one differentiation-inducing agent. In some embodiments, the at least one differentiation-inducing agent comprises all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), a retinoic acid receptor alpha (RARalpha) mimetic, navitoclax, a menin inhibitor, calcitriol, vorinostat, romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax. In one embodiment, the at least one differentiation-inducing agent comprises both ATRA and ATO. In some embodiments, the at least one iron chelator comprises deferoxamine (DFO), deferasirox (DFX), deferiprone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag. In one embodiment, the at least one iron chelator comprises DFO. In one embodiment, the at least one iron chelator comprises DFX.

[0016] In some embodiments, the at least one differentiation-inducing agent is in an amount ranging from 0.15 mg / kg / day to 50 mg / m2 / day. In one embodiment, ATO is administered at 0.15 mg / kg / day and ATRA is administered at 45 mg / m2 / day . In some embodiments, the at least one iron chelator is in an amount ranging from about 300 mg / day to about 800 mg / day.

[0017] In some embodiments, the cancer is acute myeloid leukemia (AML) or a solid tumor. In one embodiment, the cancer is AML. In some embodiments, the cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, and myelodysplastic syndrome (MDS).

[0018] In one embodiment, the composition is administered to the subject once per day for 28 days. In one embodiment, after the 28 days, the composition is administered to the subject as a maintenance therapy. In one embodiment, the composition is administered orally. In one embodiment, the subject is a human.

[0019] In one aspect, provided is a composition comprising at least one iron chelator and at least one differentiation-inducing agent for restoring terminal differentiation in cancer cells. InDocket No. 182219.00305

[0020] some embodiments, the at least one differentiation-inducing agent comprises all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), a retinoic acid receptor alpha (RARalpha) mimetic, navitoclax, a menin inhibitor, calcitriol, vorinostat, romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax. In one embodiment, the at least one differentiation-inducing agent comprises both ATRA and ATO. In some embodiments, the at least one iron chelator comprises deferoxamine (DFO), deferasirox (DFX), deferiprone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag. In one embodiment, the at least one iron chelator comprises DFO. In one embodiment, the at least one iron chelator comprises DFX.

[0021] In some embodiments, the at least one differentiation-inducing agent is in an amount ranging from about 1 pM to about 50 pM. In some embodiments, the at least one iron chelator is in an amount ranging from about 10 pM to about 100 pM.

[0022] In one embodiment, the cancer cells are human cells. In some embodiments, the cancer cells are derived from acute myeloid leukemia (AML) or a solid tumor. In one embodiment, the cancer cells are derived from AML. In some embodiments, the cancer cells are derived from breast cancer, lung cancer, colorectal cancer, or myelodysplastic syndrome (MDS).

[0023] In one embodiment, the composition is in an oral formulation. In one embodiment, the composition disclosed herein further comprises a pharmaceutically acceptable carrier or excipient.

[0024] BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1C demonstrate that activation of ferric iron-dependent fatty acid / lipid metabolism is a feature of differentiation stress mitigation in APL cells. Exposure of a cell line derived from a patient with APL (NB4) to either ATRA (IpM), ATO (2pM), iron chelator (IC) (DFO, 50pM), ferric ammonium citrate (FAC, Img / ml), ATRA (IpM) and ATO (2pM) (AA) alone, or in combination with DFO (IC+AA), or DFO and FAC (FAC+IC+AA) for 48hrs in liquid cultures; 0.01% DMSO treated cells as control (veh). (FIGS. 1A-1C). Cytospins of cells after culture were stained with May Giemsa (FIG. 1A) and quantified for presence of lipid droplets (LD) within the intact cell population (FIG. IB) as well as numbers of LD in LD+cells (FIG. IC). N=20-100 cells / image in three technical replicates.Docket No. 182219.00305

[0025] FIGS. 2A-2E illustrate that enhanced myeloid differentiation upon IC+AA treatment does not require p53. Exposure of TP53 WT (M0LM13), TP53mv (HL60), or 7 / <53null (Kasumil, Thpl) AML cells to either ATRA (IpM) and ATO (2pM) (AA), 50pM DFO (IC) alone; or in combination (IC+AA; DFO AA) for 48hrs in liquid cultures; 0.01% DMSO treated cells as control (control / veh). (FIG. 2A) Morphology by cytospin and May Giemsa stain (arrows indicate differentiation state: black - immature cells, grey- blasts with signs of myeloid maturation; black arrow in middle of second row and black arrow to the far right in the first row - terminally differentiated monocytes / neutrophils. Scale bar: 20pm. (FIGS. 2B and 2C) FACS analysis of cells after 48hrs under treatment; (FIG. 2B) CD 11b and (FIG. 2C) CKit / CD117 detection. Shown are histograms (y-axes: cell count (modal)) of mean fluorescence intensities (MFI) (x-axes); inset numbers are MFI of respective specimen. FIG.

[0026] 2D is a graph of the counts of viable (Trypan blue negative) cells after 48hrs of treatment. Shown are fold changes of HL60 (circle), Kasumil (square), and Thpl (triangle) cells compared with their cell numbers at the beginning of the culture (tO). FIG. 2E is a graph of LSC (leukemic stem cell) activity by colony formation; cells were pre-treated for 48hrs as indicated and subjected to colony -forming assays without further treatment. Graphs show numbers of colonies formed after 6-10 days. N=2 technical replicates. ** <0.05 Student’s t-test (paired) (FIG. 2D).

[0027] FIGS.3A-3C show that ferric iron chelators combined with AA drive terminal myeloid differentiation of primary AML cells. Treatment of primary peripheral blood (PB) mononuclear cells (MNC) from patient with venetoclax-resistant TP53 WT AML with ATRA (IpM) and ATO (2pM) (ATRA+ATO) alone or in combination with 50pM DFO (DFO+ATRA+ATO) or 50pM DFX (DFX+ATRA+ATO) for 48hrs in liquid culture; 0.01% DMSO treated cells as control (VTC / veh). FIG. 3A shows images of morphology by cytospin and May Giemsa stain. Scale bar: 20pm. FIG. 3B is a graph of counts of viable (Trypan blue negative) cells after 48hrs of treatment as indicated. Bars from left to right on the x-axis correspond to control, AA (ATRA+ATO), AA + DFO, and AA + DFX, respectively. FIG.3C is a graph of the number of viable cells following exposure of PB-MNC from two patients with TP53mv therapy-refractory AML (R / R AML#1 (bi-allelic TP 53 inactivation), R / R AML#2) for 48hrs.

[0028] FIG. 4 is a graph that demonstrates that DFO combined with AA induces rapid remission of relap se / refractory disease in a patient with non-APL AML. Longitudinal analysisDocket No. 182219.00305

[0029] of hematopoiesis in a 73 years-old male patient with biallelic 7 / <53mut MDS-AML (R / R AML#1) under a 28-day regimen with DFO, ATO, and ATRA. Induction therapy was started upon relapse following two lines of therapy (DO) when the patient presented 8% of the PB-MNC with abnormal myeloid blast markers CD34+CD117+. The graphs show abnormal blasts in the PB over time (D2-D23 of the treatment) by morphology using cytospin and May Giemsa stain.

[0030] FIGS. 5A-5C show that triple combination therapy is capable of inducing differentiation under reduced oxygen tension (physoxia). Exposure of HL60 cells to increasing concentrations of DFO as indicated and co-treated with ATRA (IpM) and ATO (2pM) for 96hrs (ambient O2, FIG. 5A) or 144hrs (5% O2, FIG.5B) in liquid cultures. FIGS. 5A and 5B show FACS analysis of myeloid lineage markers CDllb, CD14, CD15 and immature HSC / progenitor markers CD34, CKit / CD117, CD45Ra, CD123. FIG. 5C shows cytospins of cells after culture were stained with May Giemsa post 72hrs (ambient O2) or 144hrs (5% O2) in liquid cultures.

[0031] FIGS.6A-6F show titration of ATRA and ATO validated chosen experimental regimen and demonstrates enhanced cell eradication at >2pM ATO in the HL60 cell line. Exposure of HL60 cells to treatment for 144h (5% O2) in liquid cultures. FIG.6A is a graph of the treatment with increasing concentrations of ATO (as indicated in pM) with constant DFX (10 pM) and ATRA (IpM). Counts of viable (Pl-negative) cells after 144hrs normalized to fold change of DFX+ATRA+OpM ATO control treated cells. FIG. 6B is a graph of exposure to increasing concentrations of ATRA (as shown in pM) with DFX (lOpM) and ATO (2pM) kept constant. Counts of viable (PI negative) cells after 144hrs normalized to fold change (FC) of DFX+ATO+ OpM ATRA control treated cells. FIGS.6C-6F show FACS analysis of immature HSC / progenitor marker (CD45Ra; FIG. 6C and 6D) and myeloid marker (CD1 lb; FIGS. 6E and 6F) presentation; shown are geometric mean fluorescence intensities (MFI) values expressed as FC DFX+ATRA (FIGS. 6C and 6E) and DFX+ATO (FIGS. 6D and 6F). N=3 (technical replicates). *P<0.05; **P<0.01 by Ordinary One-way Anova testing.

[0032] FIGS. 7A-7C show that triple combination (TC) therapy is effective in eliminating venetoclax resistant AML cells ex vivo. FIG. 7A is a graph of exposure of MV4;11 venetoclax (VEN) resistant cells to ATO (2pM)+ ATRA (lpM)+DFX (lOpM) (DFXAA), ATRA+ATO (AA) ATRA alone or vehicle (VEH) for 144h (5% 02) in liquid cultures. Counts of viable (Trypan blue negative) expressed as fold change (FC) of vehicle treated control cells. FIG. 7BDocket No. 182219.00305

[0033] is a graph of LSC activity by colony formation of (VEN) resistant line. Cells were treated with DFXAA or vehicle as control for 24hrs in liquid cultures then subjected to colony forming assay without any further treatment. Graph shows colonies formed after 10 days (technical duplicate). FIG. 7C shows cytospins of cells after liquid cultures (as in FIG. 7A) were stained with May Giemsa. Scale bars indicate 20pm. Statistical assessment by Ordinary One-way Anova testing (FIG. 7A).

[0034] FIGS. 8A-8L show that ferritin heavy chain depletion sensitizes AML cells to differentiation by ATRA / ATO in a dose-dependent fashion. FIG. 8A shows quantification of Ferritin Heavy and Light chain (FTH1 / FTL) protein levels in HL60 wild type (WT) cells exposed to single agent, ATO (2pM)+ ATRA (I M) (AA), ATO (2pM)+ ATRA (l M)+DFX (lOpM) (ICAA), or vehicle controls for 72hrs (at 21% O2). FIG.8B shows validation of protein levels in FTH knockdown (KD) in HL60 cell lines at steady state by Western blot. Bars from left to right on the x-axis correspond to parental, FTH KD#18, and FTH KD #20 HL60 cells.

[0035] FIG. 8C shows LSC activity by colony formation of KD lines. Graph shows colonies formed after 9 days (error bars are STDEV of technical replicates). FIG. 8D shows cytospins of the indicated cell lines. FIGS. 8E-8H show characterization of cytosolic and mitochondrial ROS and LIP (FeRhonox-1) in FTH KD lines compared with WT using FACS at steady state grown in liquid cultures (21% O2). Bars from left to right on the x-axis correspond to parental, FTH KD#18, and FTH KD #20 HL60 cells. FIGS. 81 and 8K show live cell counts (Trypan bluenegative) of KD lines grown in liquid cultures for 48hrs (21% O2) upon exposure to ATO / ATRA. FIGS. 8 J and 8L show cytospins of KD lines exposed to ATO / ATRA in liquid cultures for 48hrs (21% O2). After culture, cells were cytospun and stained with May Giemsa. Statistical assessment by Ordinary One-way Anova (FIGS. 8C,8E-8H, 81, and 8K).

[0036] DETAILED DESCRIPTION OF THE INVENTION

[0037] This disclosure is based in part on the unexpected discovery that ferric (Fe3+) iron chelators in combination with differentiation-inducing agents (e.g., azacytidine and venetoclax) restore terminal differentiation in cancer cells. One advantage of the combination of ferric iron chelators and differentiation-inducing agents is that such combination serves as a non-cytotoxic differentiation therapy. Provided herein are compositions and methods for restoring terminal differentiation in cancer cells. Also provided are methods for treating cancer.Docket No. 182219.00305

[0038] In one aspect, provided is a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one iron chelator in combination with at least one differentiation-inducing agent. Examples of differentiation-inducing agents include, but are not limited to all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), a retinoic acid receptor alpha (RARalpha) mimetic, navitoclax, a menin inhibitor, calcitriol, vorinostat, romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax. In one embodiment, the at least one differentiation-inducing agent comprises both ATRA and ATO. In one embodiment, the ATO comprises QTX-2101 that is an oral formulation of ATO.

[0039] As used herein, the term “differentiation-inducing agent” refers to a substance (such as a small molecule) that causes an immature (unspecialized) cell to develop into a mature cell (specialized) with a specific function.

[0040] As used herein, the term “iron chelator” or “IC” refers to a natural or synthetic small molecule that binds oxidized iron ions. The binding of oxidized iron ions results in a stable complex, which can be eliminated from the body. A ferric iron chelator binds to ferric iron.

[0041] In some embodiments, the at least one iron chelator comprises deferoxamine (DFO), deferasirox (DFX), deferiprone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag. In one embodiment, the at least one iron chelator comprises DFO. In one embodiment, the at least one iron chelator comprises DFX. In some embodiments, two different iron chelators are used that have different modes of action.

[0042] In some embodiments, two different iron chelators having different modes of action are co-administered. For example, in some embodiments, a membrane-permeable ferric iron chelator (such as DFX, DFP, SIH, CP94, or HBED) is combined with a less membrane-permeable or extracellular ferric iron chelator (such as DFO) to deplete both intracellular labile iron pools and extracellular / transferrin-bound iron. In some embodiments, the two iron chelators are administered simultaneously, sequentially, or on overlapping schedules. In some embodiments, the molar ratio of the first iron chelator to the second iron chelator ranges from about 1:100 to about 100:1, such as about 1:50, 1:20, 1:10, 1:5, 1:2, 1:1, 2:1, 5:1, 10:1, 20:1, 50:1, or any ratio therebetween.Docket No. 182219.00305

[0043] In some embodiments, the iron chelator is a ferric (Fe3+)-selective chelator. In some embodiments, the iron chelator is a hexadentate chelator (such as DFO or HBED), a tridentate chelator (such as DFX or SIH), or a bidentate chelator (such as DFP, CP94, or eltrombopag). In some embodiments, the iron chelator is administered as a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or polymorph thereof, including, by way of non-limiting example, deferoxamine mesylate, deferasirox sodium, or deferiprone hydrochloride.

[0044] In some embodiments, the at least one differentiation-inducing agent is in an amount ranging from 0.15 mg / kg / day to 50 mg / m2 / day, such as about 0.15 mg / kg / day, 20 mg / kg / day, 25 mg / kg / day, 30 mg / kg / day, 35 mg / kg / day, 40 mg / kg / day, 45 mg / kg / day, 50 mg / kg / day, 5 mg / m2 / day, 10 mg / m2 / day, 15 mg / m2 / day, 20 mg / m2 / day, 25 mg / m2 / day, 30 mg / m2 / day, 35 mg / m2 / day, 40 mg / m2 / day, 45 mg / m2 / day, 50 mg / m2 / day, or any amount therebetween. In some embodiments, the at least one differentiation-inducing agent is administered to the subject orally or intravenously.

[0045] In one embodiment, ATO is administered at 0.15 mg / kg / day and ATRA is administered at 45 mg / m2 / day. ATO is orally administered to the subject, while ATRA is administered intravenously to the subject.

[0046] In one embodiment, the at least one iron chelator is in an amount ranging from about 300 mg / day to about 800 mg / day, such as about 300 mg / day, 400 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, 800 mg / day, or any amount therebetween.

[0047] In some embodiments, the at least one iron chelator is administered at a weight-based dose ranging from about 5 mg / kg / day to about 40 mg / kg / day, such as about 5, 10, 15, 20, 25, 30, 35, or 40 mg / kg / day, or any amount therebetween. In one embodiment, DFX is administered at about 7 mg / kg / day to about 28 mg / kg / day. In one embodiment, DFO is administered parenterally at about 20 mg / kg / day to about 60 mg / kg / day. In one embodiment, DFP is administered at about 25 mg / kg / day to about 100 mg / kg / day, divided into two or three doses per day. In some embodiments, the iron chelator dose is titrated based on serum ferritin, transferrin saturation, or labile plasma iron levels.

[0048] In some embodiments, the at least one differentiation-inducing agent and the at least one iron chelator are administered in a molar ratio ranging from about 1 : 1000 to about 1000: 1. In some embodiments, the at least one differentiation-inducing agent and the at least one iron chelator are administered concurrently, sequentially, or on overlapping schedules within aDocket No. 182219.00305

[0049] treatment cycle. In some embodiments, the iron chelator is administered prior to the at least one differentiation-inducing agent so as to deplete intracellular labile iron pools before differentiation induction. In some embodiments, a treatment cycle is from about 7 days to about 56 days in duration, such as about 7, 14, 21, 28, 35, 42, 49, or 56 days. In some embodiments, two or more treatment cycles are administered, optionally separated by a rest period of from about 7 to about 28 days.

[0050] In one embodiment, the at least one differentiation-inducing agent is administered to the subject simultaneously with the ferric iron chelator.

[0051] In one embodiment, the at least one iron chelator is administered orally.

[0052] In one embodiment, the composition is administered to the subject once per day for 28 days. In one embodiment, after the 28 days, the composition is administered to the subject as a maintenance therapy. In some embodiments, the maintenance therapy is administered at least once a month, twice a month, or three times a month. In some embodiments, the maintenance therapy is administered at least once a week. In some embodiments, the maintenance therapy is administered until the malignant cells (i.e., cancer cells) are substantially cleared or until the subject achieves clinical remission.

[0053] In some embodiments, the composition is administered to the subject for a treatment period of from about 7 days to about 90 days, such as about 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, or 90 days. In some embodiments, the maintenance therapy is administered for at least 3 months, at least 6 months, at least 12 months, at least 18 months, at least 24 months, or until disease progression or unacceptable toxicity. In some embodiments, the maintenance dose is the same as, lower than, or higher than the induction dose. In some embodiments, the maintenance therapy comprises monthly cycles of ATRA at about 45 mg / m2 / day for days 1-15, ATO at about 0.15 mg / kg / day, and continuous iron chelation therapy with DFX at about 720 mg / day.

[0054] In some embodiments, the cancer is acute myeloid leukemia (AML) or a solid tumor. In one embodiment, the cancer is AML. In some embodiments, the cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, and myelodysplastic syndrome (MDS). In one embodiment, the cancer is TP53 deficient (such as genetically deficient or functionally deficient).Docket No. 182219.00305

[0055] In some embodiments, the cancer is a hematologic malignancy selected from acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma. In some embodiments, the AML is non-APL AML, relapsed or refractory AML, secondary AML, therapy-related AML, or AML harboring one or more mutations in TP53, FLT3, NPM1, IDH1, IDH2, RUNX1, ASXL1, DNMT3A, TET2, or a MLL / KMT2A rearrangement. In some embodiments, the cancer is venetoclax-resistant AML, hypomethylating-agent-resistant AML, or chemotherapy -refractory AML.

[0056] In some embodiments, the cancer is a solid tumor selected from breast cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, glioblastoma, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, bladder cancer, esophageal cancer, endometrial cancer, sarcoma, and neuroblastoma. In some embodiments, the solid tumor is characterized by aberrant differentiation, by elevated intracellular labile iron, by overexpression of ferritin heavy chain (FTH1), or by NPM1 or PIN 1 dependence. Without wishing to be bound by theory, ferric iron chelation is believed to overcome the antioxidant and ferritin-mediated stress-resistance program shared across malignant cells, thereby sensitizing solid tumor cells to differentiation-inducing agents in a manner analogous to that demonstrated herein for AML.

[0057] In some embodiments, the cancer is TP53 deficient. As used herein, a TP53 deficient cancer includes a cancer in which one or both TP53 alleles carry a loss-of-function mutation, deletion, rearrangement, or epigenetic silencing event, or in which p53 protein function is impaired through MDM2 / MDM4 overexpression, viral inactivation, or post-translational modification. TP53 deficiency may be assessed by DNA sequencing, immunohistochemistry, functional reporter assay, or transcriptional signature. In some embodiments, the methods described herein are effective in subjects whose cancer cells harbor monoallelic or biallelic TP53 alterations and in subjects whose cancer cells are wild-type for TP53.

[0058] As used herein, “cancer,” “tumor,” and “malignancy” all relate equivalently to hyperplasia of a tissue or organ. If the tissue is a part of the lymphatic or immune system,Docket No. 182219.00305

[0059] malignant cells may include non-solid tumors of circulating cells. Malignancies of other tissues or organs may produce solid tumors.

[0060] In one embodiment, the subject is a human.

[0061] As used herein, the term “subject” refers to a mammal. The term “mammal” as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets, and farm animals. Mammals include, but are not limited to, a human or non-human mammal, such as a canine, bovine, equine, ovine, or feline, etc. Individuals and patients are also subjects herein.

[0062] As used herein, the term “therapeutically effective amount” refers to an amount of an agent of the present disclosure that will elicit the biological or medical response of a subject, or ameliorate symptoms, slow or delay disease progression, or prevent a disease (such as cancer), etc.

[0063] As used herein, the term “pharmaceutically acceptable carrier” refers to a carrier, diluent, excipient, or vehicle that is compatible with the active agent(s) and not deleterious to the subject to whom it is administered. Pharmaceutically acceptable carriers include, without limitation, water, saline, phosphate-buffered saline, dextrose solution, Ringer’s solution, ethanol, propylene glycol, polyethylene glycol, glycerol, dimethyl sulfoxide, vegetable oils, lipid emulsions, liposomes, lipid nanoparticles, polymeric nanoparticles, micelles, cyclodextrins, sugars (such as lactose, sucrose, mannitol, sorbitol, or trehalose), starches, celluloses (such as microcrystalline cellulose or hydroxypropyl methylcellulose), gelatin, magnesium stearate, talc, calcium phosphate, and combinations thereof. Pharmaceutically acceptable excipients include binders, fillers, disintegrants, lubricants, glidants, surfactants, preservatives, antioxidants, buffers, tonicity agents, chelating agents, sweeteners, flavoring agents, coloring agents, and coating agents.

[0064] In one aspect, provided is a composition comprising at least one iron chelator and at least one differentiation-inducing agent for restoring terminal differentiation in cancer cells. The at least one iron chelator and at least one differentiation-inducing agent can be any of those described herein. For example, the at least one iron chelator can comprise deferoxamine (DFO), DFX, deferiprone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag. The at least one differentiation-inducing agent can comprise ATRA, ATO, calcitriol, vorinostat,Docket No. 182219.00305

[0065] romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax.

[0066] In one embodiment, the cancer cells are mammalian cells. In one embodiment, the cancer cells are human cells. In some embodiments, the cancer cells are derived from AML or a solid tumor. In one embodiment, the cancer cells are derived from AML. In some embodiments, the cancer cells are derived from breast cancer, lung cancer, colorectal cancer, or myelodysplastic syndrome (MDS). In one embodiment, the cancer cells are TP53 deficient (such as genetically deficient or functionally deficient).

[0067] In one embodiment, the composition is in an oral formulation.

[0068] In some embodiments, the composition is formulated for oral, intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intranasal, transdermal, sublingual, buccal, rectal, intratumoral, or inhalation administration. In some embodiments, the oral formulation is a tablet, capsule, caplet, soft-gel capsule, lozenge, troche, granule, powder, pellet, sachet, syrup, suspension, solution, emulsion, or oral disintegrating tablet. In some embodiments, the parenteral formulation is a sterile aqueous solution, sterile suspension, lyophilized powder for reconstitution, lipid emulsion, or liposomal preparation. In some embodiments, the composition is formulated for immediate release, delayed release, sustained release, controlled release, or pulsatile release.

[0069] In some embodiments, the at least one iron chelator and the at least one differentiationinducing agent are co-formulated in a single dosage form. In some embodiments, the at least one iron chelator and the at least one differentiation-inducing agent are provided in separate dosage forms for separate, sequential, or overlapping administration. In some embodiments, the composition is provided as a kit comprising (a) the at least one iron chelator, (b) the at least one differentiation-inducing agent, and (c) instructions for use in treating cancer.

[0070] In some embodiments, the composition further comprises one or more additional therapeutic agents selected from a hypomethylating agent (such as azacitidine or decitabine), a BCL-2 inhibitor (such as venetoclax or navitoclax), an FLT3 inhibitor (such as midostaurin, gilteritinib, or quizartinib), a menin inhibitor (such as revumenib or ziftomenib), an IDH1 or IDH2 inhibitor (such as ivosidenib, olutasidenib, or enasidenib), an anti-CD33 or anti-CD123 antibody or antibody-drug conjugate, a histone deacetylase (HDAC) inhibitor (such as vorinostat or romidepsin), a checkpoint inhibitor, a vitamin D analog (such as calcitriol), anDocket No. 182219.00305

[0071] immunomodulator (such as interferon-alpha), or a chemotherapeutic agent (such as cytarabine, anthracy cline, or hydroxyurea).

[0072] As used herein, the terms “decrease,” “reduce,” “downregulate,” and “inhibit” all generally refer to a decrease by a statistically significant amount. However, for avoidance of doubt, the term “reduced,” “decrease,” “reduce,” or “inhibit” means a decrease by at least 5% (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%) as compared to a reference level, for example, a decrease by at least about 10%, a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (e.g., absent level as compared to a reference sample), or any decrease of 10-100% as compared to a reference level. In some embodiments, these terms refer to a decrease of 10-20%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 10-80%, 10-90%, 10-100%, 10-110%, 10-120%, 10-130%, 10-140%, 10-150%, 10-160%, 10-170%, 10-180%, 10-190%, 10-200%, 10-210%, 10-220%, 10-230%, 10-240%, 10-250%, 10-260%, 10-270%, 10-280%, 10-290%, or 10-300%, as compared to a reference level. In some embodiments, these terms refer to a decrease of 10-300%, 20-300%, 30-300%, 40-300%, 50-300%, 60-300%, 70-300%, 80-300%, 90-300%, 100-300%, 110-300%, 120-300%, 130-300%, 140-300%, 150-300%, 160-300%, 170-300%, 180-300%, 190-300%, 200-300%, 210-300%, 220-300%, 230-300%, 240-300%, 250-300%, 260-300%, 270-300%, 280-300%, or 290-300%, as compared to a reference level. In some embodiments, these terms refer to a decrease of 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, 90-100%, 100-110%, 110-120%, 120-130%, 130-140%, 140-150%, 150-160%, 160-170%, 170-180%, 180-190%, 190-200%, 200-210%, 210-220%, 220-230%, 230-240%, 240-250%, 250-260%, 260-270%, 270-280%, 280-290%, or 290-300%, as compared to a reference level.

[0073] As used herein, the phrases “in one embodiment,” “in various embodiments,” “in some embodiments,” and the like are used repeatedly. Such phrases do not necessarily refer to the same embodiment, but they may unless the context dictates otherwise.

[0074] As used herein, the terms “and / or”

[0075]

[0076] or means any one of the items, any combination of the items, or all of the items with which this term is associated.

[0077] As used herein and in the appended claims, the singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise.Docket No. 182219.00305

[0078] As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In some embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). Unless indicated otherwise herein, the term “about” is intended to include values, e.g., weight percents, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, the composition, or the embodiment.

[0079] As used herein, the term “each,” when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection. Exceptions can occur if explicit disclosure or context clearly dictates otherwise.

[0080] The term “about” refers to within 10%, preferably within 5%, and more preferably within 1% of a given value or range. Alternatively, the term "about" refers to within an acceptable standard error of the mean, when considered by one of ordinary skill in the art.

[0081] As disclosed herein, a number of ranges of values are provided. It is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the present disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither, or both limits are included in the smaller ranges is also encompassed within the present disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present disclosure.

[0082] The following examples serve to further illustrate the methods of the present disclosure.

[0083] EXAMPLES

[0084] Example 1. Materials and methods.Docket No. 182219.00305

[0085] This Example describes the materials and methods used in Example 2.

[0086] Chemical Reagents

[0087] Working stocks of deferoxamine mesylate (DFO) (cat. # 252750; EMD Millipore) were made fresh in IX PBS (cat. #SH3037803; Cytiva). Deferasirox; DFX (cat. # S 1712; Selleckchem) was reconstituted in DMSO (cat. #D128-500; Fisher Scientific) and stored at -80°C as single-use aliquots. Arsenic trioxide (ATO) (cat. #A3656; Sigma Aldrich) was reconstituted in IMNaOH (S318; Fisher Scientific), and single-use aliquots were stored at -80°C. All Trans Retinoic Acid (ATRA) (cat. # R2625; Millipore Sigma) was reconstituted in DMSO and single use aliquots were stored at -80°C. Working stocks of Ammonium iron (III) Citrate; FAC (cat. # F5879-100G; Sigma Aldrich) were made fresh in PBS before use. Recombinant human cytokines were reconstituted and stored according to the manufacturer’s recommendation.

[0088] Primary Cells

[0089] Human BM or PB specimens were collected at Montefiore Medical Center and the Albert Einstein College of Medicine. Primary cells were maintained in complete media containing IMDM (cat. # 10-016-CV; Corning) supplemented with 10% FBS (cat. # 16140-071; Gibco), lx Primocin (cat. #ANTPM1; Invivogen), 40 pg / mL recombinant Human LDL (cat. #02698; Stem Cell Technologies), 100 ng / mL rhSCF (cat. #300-185P-100: GeminiBio), 20 ng / mL IL-3 (rhIL3; cat. # 203IL050 / CF; R&D Systems), 50 ng / mL IL-6 (cat. # 206IL050 / CF; R&D Systems), 100 ng / mL FLT3 (cat. #308-FK; R&D Systems), 100 ng / mL TPO (cat.# 300-188P-100; GeminiBio) at 37 °C in 5% CO2 in a fully humidified atmosphere. Frozen specimens were recovered in the same medium for up to 24 hours at 37 °C in 5% CO2 in a fully humidified atmosphere before treatment. MNCs from primary specimens were isolated using low-density Ficoll-Paque Plus (1.077 g / ml, cat. #17-0300; GE Healthcare Life Sciences) gradient centrifugation at 1700 rpm for 20 min at room temperature (RT). Samples were then depleted of red blood cells using ACK Lysis Buffer (cat. #A1049201; Thermo Scientific).

[0090] Cell Lines

[0091] HL60, Molml3, Kasumil, THP1, NB-4 cells were grown in RPMI 1640 with glutamine (Corning) supplemented with 5% FBS (cat. # 16140-071; Gibco), 1%Docket No. 182219.00305

[0092] penicillin / streptomycin (cat. #30-002-Cl; Corning), at 37°C in 5% CO2 in a fully humidified atmosphere. Cells were assured to be free of Mycoplasma contamination.

[0093] Treatments

[0094] All treatments were performed in respective complete media containing cells at a density of 0.3-0.5 x 10A6 / ml. Cells were treated with IpM ATRA, 2 pM ATO, 50 pM DFO or DFX and Img / mL FAC alone or in combination (ATO+ ATRA), (ATO+ATRA+DFO / DFX) for up to 72 hours along with 0.01% DMSO treated cells as control. For ferric iron containing experiments (ATO+ATRA+DFO / DFX+FAC), cells were preloaded with FAC for 30 minutes before treatment with the rest of the regimen. Cells were processed as described below every 24 hours until viability of the control cells fell below 50%. Cells were counted using Trypan blue (cat. # 15250061; Gibco) live / dead stain.

[0095] Cytospins of cells were stained with May Giemsa (cat. # M1014242500; Fisher Scientific) and imaged with Evident APX100 microscope. FACS analysis of myeloid lineage markers CDllb, CD14, CD15, CD33 and immature HSC / progenitor markers CKit / CD117, CD34, CD 123 were performed using BD- Symphony A5 SE.

[0096] For colony formation assays using cell lines or primary cells, cells were treated as above for 24 hours and then seeded in human methylcellulose base or complete media (cat. #HSC002 / 3; R&D Systems) respectively at 37 °C in 5% CO2 in a fully humidified atmosphere. Colonies were counted after 7-14 days.

[0097] Example 2. Ferric iron chelators render AML cells, as well as solid tumor cells, highly susceptible to ATRA / ATO-driven terminal differentiation and cancer elimination.

[0098] A combined ATRA and ATO regimen has been tested and is now the frontline standard of care for patients with APL; and shows anti-cancer efficacy in small subsets of non-APL AML and breast cancer addicted to NPM1 (nucleophosmin-1) and PIN1 (peptidylprolyl cis / trans isomerase, NIMA-interacting 1), respectively. While experience with the dual combination in non-APL AML and solid cancers has remained limited, only very few patients with high-risk APL show primary or secondary resistance. Previous studies found stress-induced anti-oxidant pathway activation in healthy hematopoietic cells involving chaperone-mediated autophagy (Dong etal. Nature. 2021. 591(7848):117-23.) and a canonical limited iron response (Kao et al. Cell Stem Cell. 2024.31(3):378-97), which both converge on dictating fatty acid metabolism. This study indicates that these antioxidant pathways constitute a two-tiered stress resistance-program in malignant cells; resistance toDocket No. 182219.00305

[0099] ATRA, a pharmacological inhibitor of CMA (chaperone-mediated autophagy) (Anguiano et al. Nat Chem Biol. 2013;9(6):374-82), increased lipid droplet abundance in an APL cell line (NB4) which was resolved by ATO or iron chelator (IC; DFO) treatment (FIGS. 1A-1C), consistent with increased iron loading following DNA damaging stress in malignant cells (Tirinato etal. Elife. 2021; 10) and aged hematopoietic stem cells (HSC) (Kao etal. Cell Stem Cell. 2024. 31(3):378-97).

[0100] Moreover, it was found that treatment of NB4 cells with IC alone triggered neutrophil maturation (increased CD 15 presentation), which was augmented by concomitant ATO / ATRA (AA) treatment; in contrast, supplementation with ferric iron reversed this effect and markedly increased presentation of immature cell markers (CD34, CD123), indicating that resistance to ATRA (compromised CMA) is established via increased ferric iron abundance which blocks myeloid differentiation. It was further found that in non- APL AML cells (M0LM13; AML FAB M5a, MLL-AF9) combined IC (DFO or DFX) + ATRA + ATO treatment stimulated myeloid differentiation in a similar fashion as in NB4 APL cells.

[0101] Intriguingly, this regimen also drove terminal myeloid differentiation of AML cells lines lacking TP53 (FIG. 2A-D). Markedly compromised clonogenic capacity (a surrogate measure of leukemic stem cell (LSC) activity) was identified in p53-deficient AML cells; notably, cultures supplemented with ferric iron partially rescued colony formation of AML cells treated with IC+AA (FIG. 2E).

[0102] Ex vivo treatment of primary patient-derived bone marrow (BM) or peripheral blood (PB) mononuclear cells (MNC) validated observations made with AML cell lines: PB-MNC from a patient with venetoclax-resistant TP53WT AML showed terminal myeloid differentiation in IC (DFO or DFX) + AA cultures within 72hrs (FIG. 3A) and markedly reduced cell proliferation ex vivo within 48-96 hrs compared with AA alone of vehicle controls (FIG. 3B). Ex vivo exposure of PB-MNC from two patients with relapse / refractory TP53malAML confirmed these findings (FIG. 3C). Lastly, treatment of the first patient (R / R AML#1), a 73 yr-old male with biallelic 77<53mut MDS-AML, who had failed to respond to metronomic azacitidine and venetoclax combination therapy (Goldfinger et al.

[0103] Blood.2024.144(22):2360-3) as well as subsequent low-dose chemotherapy, showed enhanced neutrophil maturation in the PB within a week of initiating treatment with deferasirox (DFX, 720 mg / day) combined with the current induction therapy protocol for APL - ATO (0.15 mg / kg / day) and ATRA (45 mg / m2 / day) (Lo-Coco etal. The New EnglandDocket No. 182219.00305

[0104] Journal of Medicine. 2013;369(2):l 11-21) (FIG. 4). After completion of 28 days of

[0105] IC / ATRA / ATO induction therapy, the patient achieved clinical remission (CR) with clearance of morphologically aberrant myeloid blast cells (CD34+CD117+CD33+) from the BM. Reminiscent of the response seen in patients with APL under ATRA / ATO therapy (Lo-Coco et al. The New England Journal of Medicine. 2013;369(2):l 11-21; Miller et al. Am J Clin Pathol. 2019;152(5):675-85), his PB and BM myeloid cells, albeit able to terminally differentiate still originated from genetically abnormal AML clones. The patient is currently undergoing ATRA / ATO consolidation therapy (monthly cycles of ATRA (45 mg / m2 / days 1-15; ATO (0.15 mg / kg / day) and continuous iron chelation therapy (720 mg / day DFX) and is monitored for signs of disease relapse / progression.

[0106] The foregoing data indicate that ferric iron chelator use overcomes resistance to differentiation-inducing ATRA / ATO in non-APL AML cells in a p53 independent manner.

[0107] Example 3. Materials and methods.

[0108] This Example describes the materials and methods used in Example 4.

[0109] Chemical Reagents

[0110] Working stocks of deferoxamine mesylate (DFO) (cat. # 252750; EMD Millipore) were made fresh in IX PBS (cat. #SH3037803; Cytiva). Deferasirox; DFX (cat. # S1712; Selleckchem) was reconstituted in DMSO (cat. #D128-500; Fisher Scientific) and stored at -80°C as single-use aliquots. Arsenic trioxide (ATO) (cat. #A3656; Sigma Aldrich) was reconstituted in IM NaOH (S318; Fisher Scientific), and single-use aliquots were stored at -80°C. All Trans Retinoic Acid (ATRA) (cat. # R2625; Millipore Sigma) was reconstituted in DMSO and single use aliquots were stored at -80°C. Working stocks of Ammonium iron (III) Citrate; FAC (cat. # F5879-100G; Sigma Aldrich) were made fresh in PBS before use. Venetoclax (cat. # S8048, Selleckchem) was resuspended in DMSO. Recombinant human cytokines were reconstituted and stored according to the manufacturer’s recommendation.

[0111] Primary Cells

[0112] Human BM or PB specimens were collected at Montefiore Medical Center and the Albert Einstein College of Medicine. Primary cells were maintained in complete media containing IMDM (cat. # 10-016-CV; Corning) supplemented with 10% FBS (cat. # 16140-071; Gibco), lx Primocin (cat. #ANTPM1; Invivogen), 40 pg / mL recombinant Human LDLDocket No. 182219.00305

[0113] (cat. #02698; Stem Cell Technologies), 100 ng / mL rhSCF (cat. #300-185P-100: GeminiBio), 20 ng / mL IL-3 (rhIL3; cat. # 203IL050 / CF; R&D Systems), 50 ng / mL IL-6 (cat. # 206IL050 / CF; R&D Systems), 100 ng / mL FLT3 (cat. #308-FK; R&D Systems), 100 ng / mL TPO (cat.# 300-188P-100; GeminiBio) at 37°C in 5% CO2 in a fully humidified atmosphere. Frozen specimens were recovered in the same medium for up to 24 hours at 37°C in 5% CO2 in a fully humidified atmosphere before treatment. MNCs from primary specimens were isolated using low-density Ficoll-Paque Plus (1.077 g / ml, cat. #17-0300; GE Healthcare Life Sciences) gradient centrifugation at 1700 rpm for 20 min at room temperature (RT). Samples were then depleted of red blood cells using ACK Lysis Buffer (cat. #A1049201; Thermo Scientific).

[0114] Cell Lines

[0115] HL60, Molml3, Kasumil, THP1, NB-4 cells were grown in RPMI 1640 with glutamine (Corning) supplemented with 10%FBS (cat. # 16140-071; Gibco), 1% penicillin / streptomycin (cat. #30-002-Cl; Corning), at 37°C in 5% CO2 in a fully humidified atmosphere. Ven Resistant MV4;11 was grown in Iscove's Modification of DMEM With L-Glutamine, 25 mm HEPES (Corning) with 10%FBS (cat. # 16140-071; Gibco), 1% penicillin / streptomycin (cat. #30-002-Cl; Corning), at 37°C in 5% CO2 in 21% O2 or 5% O2 in a fully humidified atmosphere supplemented with 4 pM Venetoclax. Cells were assured to be free of Mycoplasma contamination.

[0116] Treatments

[0117] All treatments were performed in respective complete media containing cells at a density of 0.3-0.5 x 10A6 / ml. Cells were treated with IpM ATRA, 2 pM ATO, 50 pM or 10 pM DFO or DFX and Img / mL or 10 pg / mL FAC alone or in combination (ATO+ ATRA), (ATO+ATRA+DFO / DFX) for up to 72-144 hours along with 0.01% DMSO treated cells as control in 21% O2 or 5% O2, depending upon the experiment. For ferric iron containing experiments (ATO+ATRA+DFO / DFX+FAC), cells were preloaded with FAC for 30 minutes before treatment with the rest of the regimen. Cells were processed as described below every 24 hours until viability of the control cells fell below 50%. Cells were counted using Trypan blue (cat. # 15250061; Gibco) live / dead stain. Cytospins of cells were stained with May Giemsa (cat. # M1014242500; Fisher Scientific) and imaged with Evident APX100 microscope. FACS analysis of myeloid lineage markers CDllb, CD14, CD15, CD33 and immatureDocket No. 182219.00305

[0118] HSC / progenitor markers CKit / CD117, CD34, CD123 were performed using BD-Symphony A5 SE.

[0119] For colony formation assays using cell lines or primary cells, cells were treated as above for 24 hours and then seeded in human methylcellulose base or complete media (cat. #HSC002 / 3; R&D Systems) respectively at 37°C in 5% CO2 in a fully humidified atmosphere. Colonies were counted after 10-14 days.

[0120] Quantification of cytosolic and mitochondrial labile iron pool (LIP)

[0121] Cells were treated as above for respective time points in 21% O2 or 5% O2 at 37 degrees and then treated with 20 pM BioTracker 575 Red Fe2+ Dye (Millipore Sigma cat. # SCT030, cytosolic LIP) for 45 mins at ambient O2 in 37 degrees incubator protected from light or 5 pM Mito Ferrogreen (cat.# M489-10, Dojindo, mitochondrial LIP) in a similar manner. Cells were harvested at 1200 rpm for 5 mins, washed with PBS and resuspended in PBS+2% FBS. FACs analysis was performed using BD-Symphony A5 SE PE or FITC channels respectively.

[0122] Quantification of cytosolic and mitochondrial ROS

[0123] Cells were treated as above for respective time points in 21% O2 or 5% O2 at 37 degrees and then treated with 1 pM CellROX™ orange reagent (cat. # Cl 0443, Thermo scientific, cytosolic ROS) or 5 pM of Dihydrorhodamine 123 (cat.# D23806, Invitrogen, mitochondrial ROS) for 30 mins at 37 degrees, ambient O2, protected from light. Cells were harvested at 1200 rpm for 5 mins, washed with PBS and resuspended in PBS+2% FBS. FACs analysis was performed using BD-Symphony A5 SE, PE channel.

[0124] Western Blot

[0125] To assess FTH knockdown, steady state levels in HL60 or effect of triple combination at particular time points in HL60, cells were treated with working concentrations of ATO / ATRA or triple combination or vehicle control as stated above. Proteins were extracted from cells using RIPA buffer (EMD Millipore (cat. # 20-188) supplemented with cOmplete EDTA-free protease inhibitor cocktail (cat. # 469312400, Millipore Sigma,) and 1 mM PMSF (cat. # 93482, Sigma). Protein concentrations were determined using Protein Assay Kit (cat. # 5000002, BioRad). Prior to loading, cell extracts were mixed with appropriate volumes of 4x NuPage LDS Sample Buffer (cat. #NP0007, Invitrogen) and boiled at 95°C for 10 min. Subsequently, 60-80 pg of total proteins from each sample were separated by SDS / polyacrylamide gel electrophoresis and transferred using iBlot (cat. #IB23002). ProteinDocket No. 182219.00305

[0126] expression changes were assessed for ferritin heavy FTHl(cat # sc-376594) and FTL1 (cat # sc-74513). Signals were visualized and collected by LICOR Odyssey Fc (LI-COR Biosciences). ImageJ (imagej.nih.gov / ij / ) was used for quantification.

[0127] Crispr / Cas9-mediated knockdown of Ferritin Heavy Chain 1

[0128] Custom crRNA targeting FTH1:5’AATGGAGTGTGCATTACATT3’ (SEQ ID NO: 1) was resuspended in IDTE buffer to a final concentration of 100 pM. A crRNA:tracrRNA duplex was formed by combining 4.4 pL of 100 pM crRNA with 4.4 pL of 100 pM tracrRNA (Alt-R™ CRISPR-Cas9 tracrRNA, ATTO™ 488, cat. # IDT 10007810) and 1.2 pL IDTE buffer (final concentration 44 pM in 10 pL). The mixture was heated to 95°C for 5 minutes, then allowed to cool to room temperature on the benchtop.

[0129] Ribonucleoprotein (RNP) complexes were formed by combining each gRNA duplex with Alt-R® SpCas9 nuclease (cat. # IDT 1081060, 62 pM stock; final concentration 36 pM) to a final volume of approximately 1.2 pL per reaction. Complexes were incubated at room temperature for 10-20 minutes in the dark, then kept on ice until use.

[0130] HL60 cells were counted using trypan blue exclusion and a hemocytometer to assess viability. Cells were washed twice in RNase-free, calcium- and magnesium-free PBS by centrifugation at 150 x g for 10 minutes at room temperature to remove residual FBS, which can contain RNases. After the final wash, the cell pellet was resuspended in Neon NxT Resuspension Buffer R (cat. #N10025, Invitrogen) at a concentration of 1 x 106cells per 110 pL.

[0131] A total of 100 pL of the cell / RNP mixture (1 x io6cells) was loaded into the Neon™ NxT electroporation pipette tip (cat. #N10025, Invitrogen), taking care to avoid air bubbles. HL60 cells were electroporated at 1350 V, 35 ms, 1 pulse. Immediately following electroporation, cells were transferred to 6-well plates pre-equilibrated at 37°C and 5% CO2 containing 2 mL of antibiotic-free growth medium per well in 21% O2.

[0132] Cells were sorted by fluorescence-activated cell sorting (FACS) within 24 hours of electroporation directly into 96-well plates for single-clone isolation. Editing was confirmed by downstream genotyping and / or protein expression analysis.

[0133] Example 4. Effectiveness of triple combination therapyDocket No. 182219.00305

[0134] Further studies were performed to determine the effectiveness of triple combination therapy. A study of HL60 cells exposed to increasing concentrations of DFO (i.e., 0.1 pM, 0.5 pM, 5 pM, 10 pM, or 20 pM) and co-treated with ATRA (1 pM) and ATO (2 pM) found that the triple combination therapy is capable of inducing differentiation under reduced oxygen tension (physoxia) (FIGS. 5A-5C). Another study was performed involving the titration of the ATRA and ATO validated chosen experimental regimen in HL60 cells, which demonstrated enhanced cell eradication at >2 pM ATO (FIGS. 6A-6F). It was further determined that the triple combination therapy is effective in eliminating venetoclax resistant AML cells ex vivo (FIGS. 7A-7C). Lastly, it was also found that ferritin heavy chain depletion sensitizes AML cells to differentiation by ATRA / ATO in a dose-dependent fashion (FIGS. 8A-8L).

[0135] The foregoing examples and description of exemplary embodiments should be taken as illustrating, rather than as limiting, the present disclosure as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present disclosure as set forth in the claims. Such variations are not regarded as a departure from the scope of the disclosure, and all such variations are intended to be included within the scope of the following claims. All references cited herein are incorporated by reference in their entireties.

Claims

Docket No. 182219.00305CLAIMSWhat is claimed is:

1. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one iron chelator in combination with at least one differentiation-inducing agent.

2. The method of claim 1, wherein the at least one differentiation-inducing agent comprises all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), a retinoic acid receptor alpha (RARalpha) mimetic, navitoclax, a menin inhibitor, calcitriol, vorinostat, romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax.

3. The method of claim 1 or 2, wherein the at least one differentiation-inducing agent comprises both ATRA and ATO.

4. The method of any one of claims 1-3, wherein the at least one iron chelator comprises deferoxamine (DFO), deferasirox (DFX), def eri prone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag.

5. The method of claim 4, wherein the at least one iron chelator comprises DFO.

6. The method of claim 4, wherein the at least one iron chelator comprises DFX.

7. The method of any one of claims 1-6, wherein the at least one differentiation-inducing agent is in an amount ranging from 0.15 mg / kg / day to 50 mg / m2 / day.

8. The method of claim 7, wherein ATO is administered at 0.15 mg / kg / day and ATRA is administered at 45 mg / m2 / day.

9. The method of any one of claims 1-8, wherein the at least one iron chelator is in an amount ranging from about 300 mg / day to about 800 mg / day.

10. The method of any one of claims 1-9, wherein the cancer is acute myeloid leukemia (AML) or a solid tumor.Docket No. 182219.0030511. The method of claim 10, wherein the cancer is AML.

12. The method of claim 10, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, and myelodysplastic syndrome (MDS).

13. The method of any one of claims 1-12, wherein the composition is administered to the subject once per day for 28 days.

14. The method of claim 13, wherein after the 28 days, the composition is administered to the subject as a maintenance therapy.

15. The method of any one of claims 1-14, wherein the composition is administered orally.

16. The method of any one of claims 1-15, wherein the subject is a human.

17. A composition comprising at least one iron chelator and at least one differentiationinducing agent for restoring terminal differentiation in cancer cells.

18. The composition of claim 17, wherein the at least one differentiation-inducing agent comprises all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), a retinoic acid receptor alpha (RARalpha) mimetic, navitoclax, a menin inhibitor, calcitriol, vorinostat, romidepsin, decitabine, 13-cis-retinoic acid, rosiglitazone, interferon-alpha, azacytidine, or venetoclax.

19. The composition of claim 17 or 18, wherein the at least one differentiation-inducing agent comprises both ATRA and ATO.

20. The composition of any one of claims 17-19, wherein the at least one iron chelator comprises deferoxamine (DFO), deferasirox (DFX), deferiprone (DFP), triapine, CP94, salicylaldehyde isonicotinoyl hydrazone (SIH), HBED, curcumin, quercetin, epigallocatechin-3 -gallate (EGCG), or eltrombopag.

21. The composition of claim 20, wherein the at least one iron chelator comprises DFO.

22. The composition of claim 20, wherein the at least one iron chelator comprises DFX.Docket No. 182219.0030523. The composition of any one of claims 17-22, wherein the at least one differentiationinducing agent is in an amount ranging from about 1 pM to about 50 pM.

24. The composition of any one of claims 17-23, wherein the at least one iron chelator is in an amount ranging from about 10 pM to about 100 pM.

25. The composition of any one of claims 17-24, wherein the cancer cells are human cells.

26. The composition of any one of claims 17-25, wherein the cancer cells are derived from acute myeloid leukemia (AML) or a solid tumor.

27. The composition of claim 26, wherein the cancer cells are derived from AML.

28. The composition of claim 26, wherein the cancer cells are derived from breast cancer, lung cancer, colorectal cancer, or myelodysplastic syndrome (MDS).

29. The composition of any one of claims 17-28, wherein the composition is in an oral formulation.

30. The composition of any one of claims 17-29, further comprising a pharmaceutically acceptable carrier or excipient.